iBio (IBIO) Competitors $0.73 -0.01 (-1.62%) Closing price 07/3/2025 03:53 PM EasternExtended Trading$0.73 +0.01 (+0.82%) As of 07/3/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IBIO vs. KLRS, RENB, VRCA, HOWL, BLUE, IPA, IPSC, RNXT, VTVT, and AADIShould you be buying iBio stock or one of its competitors? The main competitors of iBio include Kalaris Therapeutics (KLRS), Renovaro (RENB), Verrica Pharmaceuticals (VRCA), Werewolf Therapeutics (HOWL), bluebird bio (BLUE), ImmunoPrecise Antibodies (IPA), Century Therapeutics (IPSC), RenovoRx (RNXT), vTv Therapeutics (VTVT), and Aadi Bioscience (AADI). These companies are all part of the "pharmaceutical products" industry. iBio vs. Its Competitors Kalaris Therapeutics Renovaro Verrica Pharmaceuticals Werewolf Therapeutics bluebird bio ImmunoPrecise Antibodies Century Therapeutics RenovoRx vTv Therapeutics Aadi Bioscience iBio (NYSE:IBIO) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment. Does the media favor IBIO or KLRS? In the previous week, iBio had 1 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 1 mentions for iBio and 0 mentions for Kalaris Therapeutics. iBio's average media sentiment score of 0.30 beat Kalaris Therapeutics' score of 0.00 indicating that iBio is being referred to more favorably in the media. Company Overall Sentiment iBio Neutral Kalaris Therapeutics Neutral Which has more risk & volatility, IBIO or KLRS? iBio has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Kalaris Therapeutics has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Do institutionals and insiders believe in IBIO or KLRS? 7.9% of iBio shares are held by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are held by institutional investors. 0.6% of iBio shares are held by company insiders. Comparatively, 32.1% of Kalaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts prefer IBIO or KLRS? iBio presently has a consensus price target of $4.30, indicating a potential upside of 490.66%. Given iBio's stronger consensus rating and higher probable upside, research analysts plainly believe iBio is more favorable than Kalaris Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iBio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Kalaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is IBIO or KLRS more profitable? Kalaris Therapeutics' return on equity of -62.08% beat iBio's return on equity.Company Net Margins Return on Equity Return on Assets iBioN/A -73.15% -45.51% Kalaris Therapeutics N/A -62.08%-54.69% Which has higher valuation & earnings, IBIO or KLRS? iBio has higher revenue and earnings than Kalaris Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioiBio$375K32.07-$24.91MN/AN/AKalaris TherapeuticsN/AN/A-$58.77MN/AN/A SummaryiBio beats Kalaris Therapeutics on 9 of the 12 factors compared between the two stocks. Get iBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IBIO vs. The Competition Export to ExcelMetriciBioPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$12.03M$790.73M$5.50B$20.64BDividend YieldN/A4.84%5.38%3.74%P/E RatioN/A1.3527.6028.10Price / Sales32.07226.97368.8154.14Price / CashN/A23.4436.6322.31Price / Book0.526.298.054.59Net Income-$24.91M-$27.73M$3.18B$986.06M7 Day Performance-3.58%1.21%2.82%2.79%1 Month Performance-26.34%9.47%3.70%5.42%1 Year Performance-63.05%7.77%35.41%14.63% iBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IBIOiBio1.7193 of 5 stars$0.73-1.6%$4.30+490.7%-63.0%$12.03M$375K0.00100KLRSKalaris TherapeuticsN/A$2.67+1.9%N/AN/A$49.93MN/A0.00110Positive NewsGap UpRENBRenovaro1.1893 of 5 stars$0.29-1.3%N/A-82.4%$49.73MN/A-0.3820Gap UpVRCAVerrica Pharmaceuticals3.9411 of 5 stars$0.53+1.4%$8.00+1,409.1%-90.8%$49.03M$7.57M-0.4440HOWLWerewolf Therapeutics3.1123 of 5 stars$1.09+6.9%$8.33+664.5%-49.5%$48.91M$1.88M-0.6540News CoveragePositive NewsBLUEbluebird bio2.1689 of 5 stars$4.97flat$44.60+797.4%N/A$48.67M$103.95M-0.13520News CoverageIPAImmunoPrecise Antibodies1.7859 of 5 stars$1.06-4.5%$4.00+277.4%+33.5%$48.51M$18.16M-0.9180News CoverageIPSCCentury Therapeutics2.7872 of 5 stars$0.56+7.7%$4.20+651.7%-75.3%$48.14M$6.59M-1.93170Gap UpHigh Trading VolumeRNXTRenovoRx2.9093 of 5 stars$1.32+2.7%$7.25+451.3%+20.5%$48.09M$40K-3.296Positive NewsVTVTvTv Therapeutics2.0731 of 5 stars$15.00+3.5%$35.50+136.7%-27.8%$47.85M$1.02M-4.989AADIAadi Bioscience0.6722 of 5 stars$1.93+1.6%$1.67-13.6%+34.3%$47.67M$25.07M-0.8540News Coverage Related Companies and Tools Related Companies KLRS Alternatives RENB Alternatives VRCA Alternatives HOWL Alternatives BLUE Alternatives IPA Alternatives IPSC Alternatives RNXT Alternatives VTVT Alternatives AADI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:IBIO) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IBIO Stock Alerts